Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

319 results about "Enhancer" patented technology

In genetics, an enhancer is a short (50–1500 bp) region of DNA that can be bound by proteins (activators) to increase the likelihood that transcription of a particular gene will occur. These proteins are usually referred to as transcription factors. Enhancers are cis-acting. They can be located up to 1 Mbp (1,000,000 bp) away from the gene, upstream or downstream from the start site. There are hundreds of thousands of enhancers in the human genome. They are found in both prokaryotes and eukaryotes.

Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase regulatory sequences for gene expression in oleaginous yeast

The regulatory sequences associated with the Yarrowia lipolytica glyceraldehyde-3-phosphate dehydrogenase (gpd) and phosphoglycerate mutase (gpm) genes have been found to be particularly effective for the expression of heterologous genes in oleaginous yeast. The promoter regions of the invention, intron and enhancer have been shown to drive high-level expression of genes involved in the production of ω-3 and ω-6 fatty acids.
Owner:EI DU PONT DE NEMOURS & CO

Eukaryotic expression vector for expressing shRNA (short hairpin Ribonucleic Acid) in manner of targeting in cancer cells

InactiveCN101993892ASolve the problem of non-specific interferenceGenetic material ingredientsMicroorganism based processesCancer cellReverse transcriptase
The invention provides a eukaryotic expression vector for expressing shRNA (short hairpin Ribonucleic Acid) in manner of targeting in cancer cells, comprising the structure as follows: (1) an expression cassette structure which is driven by a polII-type promoter and connects a fluorescent protein gene and a mirshRNA structure in series together; (2) a hTERT (human telomerase reverse transcriptase) promoter enhanced by a CMV (cytomegalovirus) enhancer and a SV40 (simian virus 40) enhancer; (3) mirshRNA structures based on mir30: mir30 left arm-shRNA-mir30 right arm, and multiple mirshRNA structures can be connected in series; (4) a Kan or Amp resistance selection marker; and (5) LR homologous recombination arms. By utilizing the method to construct the shRNA eukaryotic expression vector, one or more than one shRNA can be specifically expressed in the cancer cells in manner of targeting; normal cells are not influenced while the RNA interference and the gene therapy are carried out on the cancer cells, thereby solving the problem of non-specific interference during carrying out the gene therapy by utilizing the RNA interference and being beneficial to the research and the application of the RNA interference in the cancer gene therapy aspect.
Owner:HUNAN NENGRUN MEDICAL DIAGNOSIS TECH

Human beta-globin gene and recombinant adeno related viral vector thereof

The invention discloses a human beta globin gene containing a human beta globin gene promoter, a recombinant adeno-associated virus vector containing the human beta globin gene, and a method for preparing the recombinant vector. The recombinant adeno-associated virus vector inserts an HS2 segment, an HS3 segment and an HS4 segment of a human beta globin gene cluster enhancer core sequence and a human beta globin gene sequence containing the human beta globin gene promoter into repeated sequence ITRs on the reverse terminal of an adeno-associated virus. The recombinant vector has high transfection efficiency; and mediated exogenous genes can be expressed in vivo for a long time, have good safety and can be used for gene therapy of beta Mediterranean anemia.
Owner:DONGGUAN ZHENGXING BEITE MEDICINE TECH CO LTD

DNA (Deoxyribose Nucleic Acid) with constitutive promoter activity, application of DNA and pichia pastoris expression vector

The invention discloses a DNA (Deoxyribose Nucleic Acid) with constitutive promoter activity, application of the DNA and a pichia pastoris expression vector. The DNA has a base sequence as shown in SEQ No.1 (Sequence Number); and the application of the DNA relates to the application of the DNA in construction of the pichia pastoris (Pinchia Pastoris) expression vector. The DNA disclosed by the invention has the constitutive promoter activity, and can activate the transcription of a downstream structural gene without an inductor; the transcriptional activity shows little change in four different culture mediums, namely, ethanol, methanol, glucose and glycerol; the promoter activity is efficient, and the efficiency of the initiation transcription is four times more than the pichia pastoris GAPDH (Reduced Glyceraldehyde-phosphate Dehydrogenase) promoter. The pichia pastoris expression vector, constructed by the DNA disclosed by the invention, can efficiently express the extrinsic protein without methanol induction, and the efficiency of expressing the extrinsic protein (Enhanced Green Fluorescent Protein) is about 6 to 8 times that of the expression system of the GAPDH promoter and 1.5 to 2 times that of the expression system of a TEF1 (Transcription Enhancer Factor 1) promoter.
Owner:林影 +1

Reic-expressing adenovirus vector

An objective of the present invention is to provide an adenovirus vector expressing a REIC / Dkk-3 protein at a high level and containing a DNA construct for expression of REIC / Dkk-3 DNA, wherein the DNA construct is prepared by ligating, from the 5′ terminal side,(i) a CMV promoter,(ii) REIC / Dkk-3 DNA,(iii) a polyA addition sequence, and(iv) enhancers prepared by linking an hTERT (Telomerase Reverse Transcriptase) enhancer, an SV40 enhancer, and a CMV enhancer in this order.
Owner:UNIV OKAYAMA +1

Process for protein extraction

The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
Owner:GENENTECH INC

Parenteral formulations of peptides for the treatment of systemic lupus erythematosus

The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two of the sequences in (a) (i), (a) (ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a) (i), (a) (ii) and (b) (i) through (b) (x); and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition.
Owner:TEVA PHARMA IND LTD +1

Kit for detecting B-raf gene V600E mutation, and detection method thereof

The invention discloses a kit for detecting B-raf gene V600E mutation, and a detection method thereof. The kit comprises B-raf gene V600E mutation detection mixed liquid, wherein the B-raf gene V600Emutation detection mixed liquid comprises a B-raf gene V600E mutation detection specific primer pair, a B-raf gene specific probe, a competitive inhibition nucleotide sequence, thermostability DNA (deoxyribonucleic acid) polymerase, thermostability restriction enzyme, reaction buffer solution and reaction enhancer. The kit has the beneficial effects that an ARMS-PCR (Amplification Refractory Mutation System-Polymerase Chain Reaction) fluorescence probe technology, a competitive inhibition Blocker technology, an oligonucleotide modification technology and a TspRI restriction enzyme technology are subjected to combined adaptation, mutation samples and wild samples can be more favorably distinguished so as to realize detection sensitivity and specificity better than similar technologies or products, B-raf gene V600E site mutation can be quickly, conveniently, sensitively and economically detected, and the kit is suitable for popularization application and industrialization.
Owner:天津安必森生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products